VYNE Therapeutics  logo
VYNE Therapeutics VYNE
$ 2.84 0.71%

Quarterly report 2024-Q3
added 11-07-2024

report update icon

VYNE Therapeutics Income Statement 2011-2024 | VYNE

Annual Income Statement VYNE Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

21.9 M 7.77 M 2.92 M 257 M - - - - - - - - -

Shares

10.3 M 3.19 M 2.86 M 32.4 M - - - - - - - - -

Historical Prices

2.13 2.44 1.02 6.32 18.6 16.5 - - - - - - -

Net Income

-28.5 M -23.2 M -73.3 M -256 M -73.7 M -51.4 M -29.1 M -14.1 M -4.61 M - - - -

Revenue

424 K 477 K 931 K 21 M - 10.6 M 4.58 M 674 K - - - - -

Cost of Revenue

- - - 1.39 M - - - - - - - - -

Gross Profit

- - - 19.6 M - - - - - - - - -

Operating Income

-29.3 M -34.3 M -38.9 M -253 M -95.9 M -74.9 M -29.6 M -14.3 M -4.61 M - - - -

Interest Expense

1.39 M 363 K 5.61 M 4.39 M 921 K - 517 K 264 K - - - - -

EBITDA

- -34.2 M -38.8 M -113 M -75.5 M -54.5 M -29.6 M -14.3 M -4.61 M - - - -

Operating Expenses

- - - 133 M 76.2 M - - - - - - - -

General and Administrative Expenses

13.4 M 16.4 M 20.3 M 89.5 M 22.5 M 12.2 M 5.17 M 3.75 M 1.69 M - - - -

All numbers in USD currency

Quarterly Income Statement VYNE Therapeutics

2024-Q3 2024-Q2 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

42.6 M 42.6 M 14.1 M 3.28 M 3.27 M 3.26 M 3.23 M 3.22 M 3.22 M 3.08 M 53.6 M 52 M 51.4 M 48.9 M 43.2 M 41.9 M 34.7 M 10.6 M 9.12 M 101 M 98 M 32.2 M 23.2 M 23 M 22.9 M 17.6 M 5.3 M 5.12 M 5.09 M 5.07 M 5.28 M - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-12.2 M -9.41 M - -6.58 M -10.1 M -5.62 M - -9.46 M -8.48 M 4.67 M - -21.3 M -19.9 M -20.6 M - -24.7 M -167 M -40.2 M -21.5 M -23.2 M -19 M -15.2 M -17.6 M -12.8 M -8.35 M -12.7 M -9.28 M -8.17 M -6.15 M -5.47 M -4.84 M -3.4 M -3.56 M -2.27 M - - - - - - - - - - - - - - - - - - - -

Revenue

121 K 198 K - 114 K 135 K 99 K - 167 K 126 K 178 K - 133 K 295 K 230 K 4.29 M 3.27 M 11.7 M 1.75 M 135 K - - 308 K - 10.6 M 10.1 M 497 K 2.78 M 909 K 449 K 449 K - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - 1.05 M 795 K 601 K 24.9 M 26.8 M 179 M 41.6 M - 23.2 M 19.4 M 16.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-13.1 M -10.4 M - -6.23 M -10.3 M -5.88 M - -9.33 M -8.29 M -8.69 M - -10.8 M -9.54 M -9.76 M -22 M -23.5 M -167 M -39.9 M -37.4 M -23.2 M -19.4 M -15.9 M - -13.7 M -9.17 M -13.2 M - -8.34 M -6.22 M -5.56 M - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

934 K 1 M - 163 K 280 K 263 K - 78 K 52 K -3 K - 3.47 M 1.07 M 1.06 M - 1.09 M 1.07 M 1.07 M - 571 K 739 K 796 K - 855 K 826 K 563 K - 163 K - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - -9.11 M -8.23 M -8.65 M - -10.7 M -9.49 M -9.73 M -22 M -23.2 M -167 M -39.8 M -37.4 M -22.9 M -19.2 M -15.8 M - -13.7 M -9.17 M -13.2 M - -8.34 M -6.22 M -5.56 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - 21.9 M 17.4 M 17.2 M 19.7 M 18.4 M 13.7 M 19.3 M 13.7 M 12.3 M 9.24 M 6.67 M 6 M 5.37 M 3.7 M 3.64 M 2.3 M - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

2.96 M 3.29 M - 3.03 M 3.22 M 3.24 M - 3.95 M 4.3 M 4.42 M - 4.98 M 4.79 M 5.73 M - 19.8 M 26.5 M 25.4 M - 4.8 M 3.76 M 3.75 M - 3.04 M 3.09 M 2.7 M - 1.24 M 1.21 M 1.01 M - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency